You can buy or sell Epizyme and other stocks, options, and ETFs commission-free!
Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. The listed name for EPZM is Epizyme, Inc. Common Stock.
Robert B. Bazemore
52 Week High
52 Week Low
Return On Capital Employed Overview: Epizyme
In Q4, Epizyme (NASDAQ:EPZM) posted sales of $8.38 million. Earnings were up 14.23%, but Epizyme still reported an overall loss of $62.14 million. Epizyme colle
-$0.58 per share
-$0.65 per share